Ziresovir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ziresovir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ziresovir can convert its Small molecule drug profile and RSV F protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ziresovir (query alias: Ziresovir) |
|---|---|
| Modality / target | Small molecule drug; RSV F protein; Respiratory syncytial virus F protein inhibitors |
| Highest global status | NDA/BLA |
| Originator | F. Hoffmann-La Roche Ltd. |
| Active developers | Shanghai Ark Biopharmaceutical Co., Ltd. |
The MCP disease footprint includes Respiratory Syncytial Virus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06775405 | Phase 3 | Recruiting | 180 | Change from baseline in the Wang bronchiolitis clinical score |
| NCT07658534 | Phase 2/3 | Recruiting | 290 | Time from first dose to resolution of LRTD symptoms |
| NCT06942299 | Phase 2 | Completed | 25 | Incidence and severity of AE and SAE of subjects during the study period |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up
Phase 3; n=188; evaluation: Positive. Reported fields: WBCS(3-day; ITT-i) = -2.2 Point (95%CI, -2.8 to -1.7); WBCS(3-day; ITT-i) = -3.5 Point (95%CI, -3.9 to -3.1)
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection
Phase 3; n=244; evaluation: Positive. Reported fields: Adverse Event: Resistance-associated mutations = Resistance-associated mutations were identified in 15 participants (9%) in the ziresovir group ; Adverse Event: Resistance-associated mutations = Resistance-associated mutations were identified in 15 participants (9%) in the ziresovir group
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection
Phase 3; n=302; evaluation: Positive. Reported fields: Wang bronchiolitis clinical score(3-day) = −2.7 Point (95%CI, −3.1 - −2.2); Wang bronchiolitis clinical score(3-day) = −3.4 Point (95%CI, −3.7 - −3.1)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ziresovir addresses Respiratory Syncytial Virus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-05-24 | 爱科百发与合全药业就爱司韦®商业化供应签订合作协议 | NDA/BLA | Financial terms not disclosed |
| 2014-02-01 | Ark Biosciences licensed AK0529 from Roche | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
